Back to top
more

Seattle Genetics, Inc. (SGEN)

(Delayed Data from NSDQ)

$67.25 USD

67.25
574,388

+0.33 (0.49%)

Updated May 3, 2019 04:00 PM ET

After-Market: $67.27 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Will Seattle Genetics Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor Seattle Genetics

Analysts Estimate Seattle Genetics (SGEN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Seattle Genetics (SGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seattle Genetics Gets Early FDA Nod for Breast Cancer Drug

by Zacks Equity Research

The FDA grants accelerated nod to Seattle Genetics' (SGEN) Tukysa in combination with Herceptin and Xeloda to treat adults with advanced unresectable metastatic HER2-positive breast cancer.

Seattle Genetics Issue Update on Padcev Label Expansion Study

by Zacks Equity Research

Seattle Genetics (SGEN) may receive an expedited approval pathway for Padcev combo to treat patients with locally advanced/metastatic urothelial cancer in the first-line setting in the United States.

Why Is Seattle Genetics (SGEN) Down 3.2% Since Last Earnings Report?

by Zacks Equity Research

Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biotech Stock Roundup: INCY's Solid Q4 Results, EPZM & SGEN's Pipeline Updates

by Zacks Equity Research

It was a low-key week for the biotech sector with updates from just a few small biotech companies.

Seattle Genetics (SGEN) Q4 Earnings Top, Adcetris Drives Sales

by Zacks Equity Research

Seattle Genetics (SGEN) rides high on Q4 earnings and revenue beat.

Seattle Genetics (SGEN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Seattle Genetics (SGEN) delivered earnings and revenue surprises of 51.11% and 29.44%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Why Seattle Genetics (SGEN) Might Surprise This Earnings Season

by Zacks Equity Research

Seattle Genetics (SGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Seattle Genetics (SGEN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Seattle Genetics (SGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Roche's (RHHBY) Lymphoma Drug Polivy Gets Approval in Europe

by Zacks Equity Research

Roche (RHHBY) obtains approval for Polivy in Europe for the treatment of adult patients with R/R DLBCL.

Seattle Genetics Up More Than 40% in the Past Year: Here's Why

by Zacks Equity Research

Seattle Genetics' (SGEN) Adcetris registers strong sales in 2019. The company wins an accelerated approval for Padcev to treat urothelial cancer while other pipeline candidates also progress well.

Astellas Acquires Xyphos to Boost Immuno-oncology Pipeline

by Zacks Equity Research

Astellas (ALPMY) acquires Xyphos and gains the latter's novel and proprietary ACCEL technology platform.

Seattle Genetics Submits NDA to FDA for Tucatinib Combo

by Zacks Equity Research

Seattle Genetics (SGEN) submits an NDA to the FDA for tucatinib in combination with Herceptin and Xeloda seeking approval to treat locally advanced/metastatic HER2-positive breast cancer.

Seattle Genetics Gets Speedy FDA Nod for Bladder Cancer Drug

by Zacks Equity Research

The FDA grants accelerated nod to Seattle Genetics' (SGEN) Padcev to treat urothelial cancer. It also assigns Breakthrough Therapy tag to tucatinib for advanced/metastatic HER2-positive breast cancer.

Biotech Stock Roundup: Pipeline Updates From BIIB, AXSM, CARA, Collaborations & More

by Zacks Equity Research

Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.

Seattle Genetics, Astellas Tie Up With Merck for Cancer Study

by Zacks Equity Research

Seattle Genetics (SGEN) and Astellas team up with Merck for a late-stage study to evaluate the enfortumab vedotin and Keytruda combo in patients with previously untreated metastatic urothelial cancer.

Seattle Genetics (SGEN) Up 15.7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Seattle Genetics (SGEN) Q3 Loss Widens, Revenues Top Mark

by Zacks Equity Research

Seattle Genetics (SGEN) incurs wider-than-expected loss in third-quarter 2019 but rides high on revenue beat.

Seattle Genetics (SGEN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Seattle Genetics (SGEN) delivered earnings and revenue surprises of -45.95% and 1.26%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Biotech Stock Roundup: BIIB Up on AD Data, ALXN to Buy ACHN & Other Pipeline Updates

by Zacks Equity Research

Key highlights of the past week include acquisition news, and regulatory and pipeline updates.

Seattle Genetics Begins Phase III Study on Tucatinib Combo

by Zacks Equity Research

Seattle Genetics (SGEN) doses the first patient in the phase III HER2CLIMB-02 study on tucatinib in combination with Roche's Kadcyla for treating advanced/metastatic HER2-positive breast cancer.

Seattle Genetics Up More Than 20% in 3 Months: Here's Why

by Zacks Equity Research

Seattle Genetics' (SGEN) only marketed product, Adcetris, has been performing well since its launch. The company's established pipeline candidates are also progressing well.

Immunomedics (IMMU) Reports Interim Urothelial Cancer Data

by Zacks Equity Research

Immunomedics (IMMU) presents interim data on sacituzumab govitecan in patients with metastatic urothelial cancer. The company also inks two deals.

Seattle Genetics Up on Positive Data From Bladder Cancer Study

by Zacks Equity Research

Seattle Genetics (SGEN) and Astellas' enfortumab vedotin in combination with Merck's Keytruda proves safety in a phase I study as a first-line treatment for advanced bladder cancer. Shares up.